ワンクリックでManusで任意のスキルを実行

opencrispr-gene-editors

スター31

フォーク8

更新日2026年6月18日 19:20

Evaluate and operate released Profluent OpenCRISPR gene-editing systems, especially OpenCRISPR-1, for controlled research workflows using its published Cas9-like protein, compatible guide RNA designs, protocols, licensing, specificity testing, and experimental validation. Use when comparing OpenCRISPR-1 with SpCas9, planning nonclinical editing studies, or assessing use in nuclease, nickase, deactivated, base, prime, or epigenome-editing contexts.

インストール

Codex または Claude でインストールこの Prompt をコピーして Codex、Claude、または他のアシスタントに貼り付けると、Skill ページを確認してインストールできます。

Manusで実行

ソース

mdbabumiamssm

mdbabumiamssm/LLMs-Universal-Life-Science-and-Clinical-Skills-

GitHub リポジトリを開く Creator のリポジトリを見る

ダウンロード

Manusで実行

OpenCRISPR Gene Editors

Use only released OpenCRISPR systems under institutional biosafety, ethical, and legal oversight. This skill does not authorize de novo editor engineering or clinical use.

Workflow

Define the research purpose, cell or organism system, genomic target, delivery method, and whether nuclease, nickase, or deactivated activity is required.
Confirm that the released system and NGG PAM preference fit the target and that the guide design is compatible with the intended editor configuration.
Obtain sequence and protocol materials from the official release and record the repository revision, construct, guide, and license status.
Design a comparison that includes a validated reference editor, mock control, non-targeting guide, positive control, and multiple independent guides when possible.
Pre-register on-target efficiency, indel spectrum, bystander effects, off-target assessment, viability, innate immune response, and delivery metrics.
Use orthogonal assays for editing efficiency and specificity; do not rely on a single amplicon, prediction model, or reporter.
Confirm the exact editor state and fusion architecture before interpreting base, prime, or epigenome-editing results.
Stop escalation when safety, specificity, or reproducibility thresholds are not met.

Guardrails

Do not use this skill to design pathogen-enhancing edits, transmissible systems, or unapproved human germline or clinical interventions.
Do not assume canonical SpCas9 guide compatibility guarantees equivalent activity or specificity.
Do not omit off-target and structural-variant assessment for consequential experiments.
Follow institutional biosafety committee, ethics, material-transfer, and licensing requirements.
Treat commercial therapeutic use as license-controlled even though sequences are public.
Require qualified experimental review before ordering constructs or initiating wet-lab work.

Output Contract

Return the use case, editor configuration, licensing status, guide and control strategy, assay plan, predefined acceptance thresholds, biosafety review, failure criteria, and evidence gaps.

Read references/operations.md for release facts, access, validation considerations, and canonical sources.

このリポジトリの他の Skills

同じリポジトリ

medsam2-3d-segmentation

mdbabumiamssm/LLMs-Universal-Life-Science-and-Clinical-Skills-

Operate MedSAM2 for promptable segmentation of 3D medical images and medical videos, including CT lesion propagation, MRI volumes, RECIST-guided prompts, efficient CPU-oriented variants, training, and 3D Slicer integration. Use when generating or validating volumetric masks from sparse prompts or propagating masks through image slices or video frames.

2026-06-1831

monai-medical-imaging

mdbabumiamssm/LLMs-Universal-Life-Science-and-Clinical-Skills-

Build reproducible healthcare imaging pipelines with Project MONAI for DICOM, NIfTI, pathology, and multidimensional imaging tasks including preprocessing, augmentation, training, sliding-window inference, evaluation, model bundles, labeling, and deployment. Use when implementing medical image classification, segmentation, registration, detection, generative, or foundation-model workflows in PyTorch.

2026-06-1831

txgemma-therapeutics

mdbabumiamssm/LLMs-Universal-Life-Science-and-Clinical-Skills-

Operate Google TxGemma prediction and chat models for therapeutic property prediction across small molecules, proteins, nucleic acids, diseases, targets, and cell lines. Use when formatting Therapeutics Data Commons tasks, choosing TxGemma model size or variant, running local or Model Garden inference, fine-tuning on private therapeutic data, or evaluating TxGemma in drug-discovery workflows.

2026-06-1831

transcriptformer-cell-embeddings

mdbabumiamssm/LLMs-Universal-Life-Science-and-Clinical-Skills-

Operate CZI TranscriptFormer cross-species generative single-cell models to produce cell embeddings, contextual gene embeddings, likelihoods, zero-shot classifiers, disease-state representations, and regulatory analyses from raw-count AnnData files. Use when selecting TF-Sapiens, TF-Exemplar, or TF-Metazoa, processing in- or out-of-distribution species, or scaling embedding extraction across GPUs.

2026-06-1831

protenix-structure-prediction

mdbabumiamssm/LLMs-Universal-Life-Science-and-Clinical-Skills-

Operate ByteDance Protenix-v2 for open biomolecular structure prediction of proteins, antibodies, nucleic acids, ligands, and complexes using JSON inputs, MSA and template features, constraints, and inference-time sampling. Use when running Protenix locally or through its server, comparing AlphaFold3-style open models, or building reproducible co-folding evaluations.

2026-06-1831

medgemma-health-ai

mdbabumiamssm/LLMs-Universal-Life-Science-and-Clinical-Skills-

Build and evaluate medical text and vision applications with Google MedGemma, including MedGemma 1.5 workflows for CT, MRI, whole-slide pathology, longitudinal chest X-rays, lab reports, and EHR text. Use when prototyping, fine-tuning, deploying, or validating MedGemma-based health AI under clinical data and safety controls.

2026-06-1831

name

opencrispr-gene-editors

description

OpenCRISPR Gene Editors

Use only released OpenCRISPR systems under institutional biosafety, ethical, and legal oversight. This skill does not authorize de novo editor engineering or clinical use.

Workflow

Define the research purpose, cell or organism system, genomic target, delivery method, and whether nuclease, nickase, or deactivated activity is required.
Confirm that the released system and NGG PAM preference fit the target and that the guide design is compatible with the intended editor configuration.
Obtain sequence and protocol materials from the official release and record the repository revision, construct, guide, and license status.
Design a comparison that includes a validated reference editor, mock control, non-targeting guide, positive control, and multiple independent guides when possible.
Pre-register on-target efficiency, indel spectrum, bystander effects, off-target assessment, viability, innate immune response, and delivery metrics.
Use orthogonal assays for editing efficiency and specificity; do not rely on a single amplicon, prediction model, or reporter.
Confirm the exact editor state and fusion architecture before interpreting base, prime, or epigenome-editing results.
Stop escalation when safety, specificity, or reproducibility thresholds are not met.

Guardrails

Do not use this skill to design pathogen-enhancing edits, transmissible systems, or unapproved human germline or clinical interventions.
Do not assume canonical SpCas9 guide compatibility guarantees equivalent activity or specificity.
Do not omit off-target and structural-variant assessment for consequential experiments.
Follow institutional biosafety committee, ethics, material-transfer, and licensing requirements.
Treat commercial therapeutic use as license-controlled even though sequences are public.
Require qualified experimental review before ordering constructs or initiating wet-lab work.

Output Contract

Return the use case, editor configuration, licensing status, guide and control strategy, assay plan, predefined acceptance thresholds, biosafety review, failure criteria, and evidence gaps.

Read references/operations.md for release facts, access, validation considerations, and canonical sources.